Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pharvaris (PHVS)
NASDAQ:PHVS
Holding PHVS?
Track your performance easily
PHVS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.00 - $33.00
Previous Close$21.09
Volume627.95K
Average Volume (3M)77.27K
Market Cap
$1.14B
Enterprise Value$705.47M
Total Cash (Recent Filing)€391.23M
Total Debt (Recent Filing)€238.91K
Price to Earnings (P/E)―
Beta-1.58
Next Earnings
Apr 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.46
Shares Outstanding52,290,212
10 Day Avg. Volume113,214
30 Day Avg. Volume77,266
Standard Deviation0.71
R-Squared0.04
Alpha0.11
Financial Highlights & Ratios
Price to Book (P/B)2.87
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$36.17Price Target Upside85.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Pharvaris News
PremiumCompany Announcements
Pharvaris Reveals Positive HAE Drug Data
Bulls Say, Bears Say
Bulls Say
ConvenienceThe convenience of deucrictibant's daily oral administration is likely to drive its adoption over injectable options for hereditary angioedema.
EfficacyDeucrictibant reduced attack symptoms by 50% in about 4 hours in Phase 2 trials, significantly faster than its closest competitor.
Long-term Safety And EfficacyLong-term data show deucrictibant reduces attack rates by 93% from baseline, reinforcing its compelling profile and competitive edge.
Bears Say
Clinical UpdatesClinical updates largely in-line with previous phase 2 data.
Data AnalysisAwaiting additional placebo-controlled data before revisiting the DCF model.
Stock RecommendationMaintained Underperform rating with a $14 price objective.
---
Ownership Overview
0.00%
Insiders
7.91% Mutual Funds
68.44% Other Institutional Investors
23.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PHVS FAQ
What was Pharvaris’s price range in the past 12 months?
Pharvaris lowest stock price was $15.00 and its highest was $33.00 in the past 12 months.
What is Pharvaris’s market cap?
Currently, no data Available
When is Pharvaris’s upcoming earnings report date?
Pharvaris’s upcoming earnings report date is Apr 24, 2025 which is in 215 days.
How were Pharvaris’s earnings last quarter?
Pharvaris released its earnings results on Aug 14, 2024. The company reported -$0.61 earnings per share for the quarter, beating the consensus estimate of -$0.612 by $0.002.
Is Pharvaris overvalued?
According to Wall Street analysts Pharvaris’s price is currently Undervalued.
Does Pharvaris pay dividends?
Pharvaris does not currently pay dividends.
What is Pharvaris’s EPS estimate?
Pharvaris’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharvaris have?
Pharvaris has 54,007,710 shares outstanding.
What happened to Pharvaris’s price movement after its last earnings report?
Pharvaris reported an EPS of -$0.61 in its last earnings report, beating expectations of -$0.612. Following the earnings report the stock price went down -7.549%.
Which hedge fund is a major shareholder of Pharvaris?
Among the largest hedge funds holding Pharvaris’s share is Viking Global Investors LP. It holds Pharvaris’s shares valued at 69M.
---
Pharvaris Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.17 (85.39% Upside)
$36.17 (85.39% Upside)
Hedge Fund Trend
Increased
By 335.7K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-1.44%
12-Months-Change
Fundamentals
Return on Equity
-45.15%
Trailing 12-Months
Asset Growth
82.16%
Trailing 12-Months
Company Description
Pharvaris
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
---
PHVS Stock 12 Month Forecast
Average Price Target
$36.17
▲(85.39% Upside)
Technical Analysis
Best Analysts Covering PHVS
1 Year
1 Year Success Rate
14/20 ratings generated profit
1 Year Average Return
+66.88%
reiterated a buy rating 16 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +66.88% per trade.
---